目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing prevalence of chronic diseases
3.2.1.2. Increasing investment in biologics research and development
3.2.2. Market Restraint Analysis
3.2.2.1. High development cost
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
3.4. Pipeline Analysis

Chapter 4. Indication Business Analysis
4.1. Bispecific Antibodies Market: Indication Movement Analysis
4.2. Cancer
4.2.1. Cancer Market, 2018 - 2030 (USD Million)
4.3. Inflammatory & Autoimmune Disorders
4.3.1. Inflammatory & Autoimmune Disorders Market, 2018 - 2030 (USD Million)
4.4. Others
4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis
5.1. Bispecific Antibodies Market Share By Region, 2022 & 2030
5.2. North America
5.2.1. North America Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.2.2. The U.S.
5.2.2.1. Key Country Dynamics
5.2.2.2. Target Disease Prevalence
5.2.2.3. Competitive Scenario
5.2.2.4. Regulatory Framework
5.2.2.5. U.S. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.2.3. Canada
5.2.3.1. Key Country Dynamics
5.2.3.2. Target Disease Prevalence
5.2.3.3. Competitive Scenario
5.2.3.4. Regulatory Framework
5.2.3.5. Canada Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.3. Europe
5.3.1. Europe Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.3.2. UK
5.3.2.1. Key Country Dynamics
5.3.2.2. Target Disease Prevalence
5.3.2.3. Competitive Scenario
5.3.2.4. Regulatory Framework
5.3.2.5. UK Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.3.3. Germany
5.3.3.1. Key Country Dynamics
5.3.3.2. Target Disease Prevalence
5.3.3.3. Competitive Scenario
5.3.3.4. Regulatory Framework
5.3.3.5. Germany Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.4. Asia Pacific
5.4.1. Asia Pacific Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.4.2. Japan
5.4.2.1. Key Country Dynamics
5.4.2.2. Target Disease Prevalence
5.4.2.3. Competitive Scenario
5.4.2.4. Regulatory Framework
5.4.2.5. Japan Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.4.3. China
5.4.3.1. Key Country Dynamics
5.4.3.2. Target Disease Prevalence
5.4.3.3. Competitive Scenario
5.4.3.4. Regulatory Framework
5.4.3.5. China Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.5. Rest of the world
5.5.1. Rest of the world Bispecific Antibodies Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Strategy Mapping
6.3. Company Market Share Analysis, 2022
6.4. Company Profiles/Listing
6.4.1. Amgen
6.4.1.1. Overview
6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.1.3. Product Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. Roche
6.4.2.1. Overview
6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.2.3. Product Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. Genentech
6.4.3.1. Overview
6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.3.3. Product Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. Akeso, Inc
6.4.4.1. Overview
6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.4.3. Product Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Janssen
6.4.5.1. Overview
6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.5.3. Product Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. Taisho Pharmaceutical
6.4.6.1. Overview
6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.6.3. Product Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. Immunocore
6.4.7.1. Overview
6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.7.3. Product Benchmarking
6.4.7.4. Strategic Initiatives

List of Tables
TABLE 1. List of abbreviations
TABLE 2. Global bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 3. North America bispecific antibodies market, by country, 2018 - 2030 (USD Million)
TABLE 4. North America bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 5. U.S. bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 6. Canada bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 7. Europe bispecific antibodies market, by country, 2018 - 2030 (USD Million)
TABLE 8. Europe bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 9. UK bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 10. Germany bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 11. Asia Pacific bispecific antibodies market, by country, 2018 - 2030 (USD Million)
TABLE 12. Japan bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 13. China bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
TABLE 14. Rest of World bispecific antibodies market, by country, 2018 - 2030 (USD Million)

List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 Market formulation & validation
FIG. 7 Bispecific Antibodies market segmentation
FIG. 8 Market snapshot, 2022
FIG. 9 Market trends & outlook
FIG. 10 Market driver relevance analysis (current & future impact)
FIG. 11 Market restraint relevance analysis (current & future impact)
FIG. 12 PESTEL analysis
FIG. 13 Porter’s five forces analysis
FIG. 14 Global bispecific antibodies market: Indication movement analysis
FIG. 15 Global bispecific antibodies market, for cancer, 2018 - 2030 (USD Million)
FIG. 16 Global bispecific antibodies market, for Inflammatory & Autoimmune Disorders, 2018 - 2030 (USD Million)
FIG. 17 Global bispecific antibodies market, for others 2018-2030, (USD Million)
FIG. 18 Global bispecific antibodies market: Region movement analysis
FIG. 19 North America bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 20 U.S. bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 21 Canada bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 22 Europe bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 23 Germany bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 24 UK bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 25 Asia Pacific bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 26 Japan bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 27 China bispecific antibodies market, 2018 - 2030 (USD Million)
FIG. 28 Rest of the World bispecific antibodies market, 2018 - 2030 (USD Million)